company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,42000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,42000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,42000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2785000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7500000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10285000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10243000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,508000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-28720000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-29227000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-39470000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-16245000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23225000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,76394000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,28806000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,81975000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,856000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,81119000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,50.68
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,50.68
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1605324.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,50.68
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,91000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,91000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,91000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4645000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4703000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9348000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9257000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,929000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,32000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,141000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-756000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10013000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10013000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10013000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,286000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10299000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,16900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.61
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.61
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,16817841.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 07:03:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.61
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,91000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,91000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,91000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4075000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8306000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12381000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12290000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,880000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,39000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-351000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1192000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13482000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13482000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13482000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13482000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,24500000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.55
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,24500000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.55
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,24464281.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 18:10:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.55
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1090000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1090000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1090000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8684000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5150000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13834000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12744000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,804000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,30000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-9271000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-10045000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22789000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22789000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22789000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,-1000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-9277000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13511000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,17440910.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.56
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,17440910.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.56
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,17400000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.49
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,281000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,281000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,277000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12214000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3542000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15756000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15479000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3306000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,55000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-8627000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11878000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27357000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27357000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27357000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27357000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,30897075.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.89
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,30897075.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.89
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,30700000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q2,2013-04-01,2013-06-30,2014-08-12 16:16:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.89
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1257000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1257000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,33000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,33000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1224000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14620000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3779000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18399000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17175000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2870000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,96000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-4147000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6921000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24096000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24096000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24096000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24096000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,30941404.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.78
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,30941404.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.78
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,30900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 16:30:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.78
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10334000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10334000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1067000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1067000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9267000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15223000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5402000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20625000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11358000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10496000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,96000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-19062000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-29462000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-40820000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40820000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40820000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-18414000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22406000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,31848299.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.23
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,31848299.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.23
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,31800000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.63
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9081000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9081000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,494000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,494000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8587000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17527000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4482000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22009000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13422000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,102000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,677000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2121000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15543000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15543000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15543000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15543000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41129055.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41129055.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 17:27:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,29675000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29675000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1661000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1661000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,28014000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,19581000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4677000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24258000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3756000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1317000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,85000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,678000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-554000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3202000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3202000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3202000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3202000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42056285.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.08
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42372137.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.08
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40000000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 20:43:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.08
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22687000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22687000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1321000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1321000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21366000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17445000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4657000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22102000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-736000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2475000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,78000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,762000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1635000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2371000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2371000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2371000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2371000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42900269.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.06
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42900269.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.06
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39500000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q3,2014-07-01,2014-09-30,2017-01-20 17:26:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.06
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31235000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31235000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2282000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2282000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,28953000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18059000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5770000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23829000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5124000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1521000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,83000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,731000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-707000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4417000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,630000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3787000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3787000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3787000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42260896.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.1
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42260896.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.1
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42000000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.1
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,28738000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,28738000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1618000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1618000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27120000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,19403000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3683000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23086000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4034000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3274000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,113000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-49000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3210000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,824000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,86000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,738000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,738000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,738000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44563299.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.02
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44901298.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.02
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q1,2015-01-01,2015-03-31,2017-01-20 17:28:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.02
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,35678000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,35678000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1762000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1762000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,33916000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23194000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6878000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30072000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3844000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1345000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,137000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,26000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1182000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2662000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,225000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2437000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2437000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2437000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47911932.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52273549.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48700000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q2,2015-04-01,2015-06-30,2017-01-20 18:14:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,39362000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,39362000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2248000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2248000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37114000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,22900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9129000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,32029000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5085000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1315000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,169000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,119000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1027000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4058000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,142000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3916000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3916000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3916000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48515071.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.08
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51590797.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.08
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49000000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q3,2015-07-01,2015-09-30,2017-01-20 17:26:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.08
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,43687000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,43687000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2795000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2795000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,40892000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23566000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9445000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33011000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,7881000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1174000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,224000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,135000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-815000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,7066000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,213000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6853000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6853000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6853000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47485258.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.14
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51160380.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.14
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48100000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.14
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,44194000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,44194000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2035000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2035000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,42159000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25160000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10562000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35722000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6437000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1840000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,331000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,97000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1412000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5025000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,200000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4825000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4825000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4825000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,49240099.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.1
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51152072.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.08
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48300000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q1,2016-01-01,2016-03-31,2017-01-20 17:28:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.1
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,51626000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,51626000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2751000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2751000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,48875000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26121000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11109000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37230000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11645000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1477000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,363000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,125000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-989000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,10656000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,405000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,10251000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,10251000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,10251000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,49427825.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.21
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51745342.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.18
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48800000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q2,2016-04-01,2016-06-30,2017-01-20 18:14:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.21
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56810000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56810000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3428000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3428000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,53382000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25675000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7868000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33543000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,19839000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1206000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,378000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,125000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-703000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,19136000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-42690000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,61826000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,61826000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,61826000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,49516595.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.25
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51974435.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.18
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49500000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 17:39:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.25
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,272451000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,272451000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3772000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3772000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,268679000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,29054000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13252000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,210078000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,252384000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,16295000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1239000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,395000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,101000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-743000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,15552000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1233000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,14319000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,14319000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,14319000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,49472434.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.28
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51708983.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49600000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.28
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,57576000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,57576000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2949000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2949000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,54627000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28238000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9601000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37839000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,16788000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1150000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,531000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,54000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-565000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,16223000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5926000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,10297000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,10297000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,10297000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50158634.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.21
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52764442.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49000000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 13:57:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.21
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75829000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75829000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3861000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3861000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,71968000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,35078000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10823000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45901000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,26067000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,321000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,656000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,23000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,358000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,26425000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,9057000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,17368000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,17368000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,17368000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50530968.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.34
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53223714.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51100000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 15:17:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.34
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,80398000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,80398000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4251000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4251000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,76147000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40825000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12980000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53805000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,22342000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,246000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,814000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,568000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,22910000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6949000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15961000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,15961000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,15961000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51046375.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.31
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53628389.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.29
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51500000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 09:49:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.31
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,88435000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,88435000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4154000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4154000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,84281000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,33764000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16173000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49937000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,34344000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-1717000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2001000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1000000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,716000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,35060000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,21402000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,13658000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,13658000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,13658000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50756603.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.27
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53301150.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.28
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50700000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.27
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,89120000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,89120000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3278000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3278000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,85842000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,36849000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18908000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-1309000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,54448000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,31394000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-212000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-212000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,31182000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4830000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,26352000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,26352000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,26352000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51536474.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.51
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53788346.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.49
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51700000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 15:38:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.51
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,97830000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,97830000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3683000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3683000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,94147000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40097000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20038000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-1758000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58377000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,35720000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1864000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1864000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,33856000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3119000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,30737000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,30737000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,30737000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51919894.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.59
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54203308.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.57
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52100000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 11:02:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.59
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,100227000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,100227000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4207000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4207000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,96020000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40892000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20422000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-2769000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58545000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,37475000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1104000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1104000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,36371000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8360000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,28011000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,28011000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,28011000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52227630.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.54
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54239847.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.52
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51900000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 14:59:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.54
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,121720000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,121720000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4188000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4188000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,117532000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,42050000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29841000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,5836000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,77727000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,39855000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1088000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1088000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,38767000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,12874000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,25893000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,25893000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,25893000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51989824.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.49
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54098872.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.47
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52100000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.49
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,83099000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,83099000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3684000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3684000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,79415000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40968000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15394000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-2375000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53987000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,25428000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1189000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1189000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,24239000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5899000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18340000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18340000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18340000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52336443.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.35
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53985385.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.34
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52400000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q1,2019-01-01,2019-03-31,2020-05-15 16:28:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.35
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,102358000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,102358000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4044000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4044000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,98314000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,41083000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16970000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-2337000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,55716000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,42598000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,148000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,148000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,42746000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10019000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,32727000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,32727000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,32727000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52385590.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.62
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53912977.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.61
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52800000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 11:02:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.62
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,100034000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,100034000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4819000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4819000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,95215000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40649000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16943000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-2106000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,55486000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,39729000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-139000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-139000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,39590000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10730000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,28860000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,28860000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,28860000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52453384.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.55
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53805838.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.54
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52500000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 14:59:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.55
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,107264000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,107264000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4113000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4113000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,103151000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,35725000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19792000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,6818000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,62335000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,40816000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,96000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,96000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,40912000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7783000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,33129000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,33129000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,33129000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52412181.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.64
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53816754.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.61
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52300000.0
Supernus Pharmaceuticals Inc,SUPN,,0001356576,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.64
